IT-ACTS: A Highly Adaptive and Versatile Cell-Therapy Platform

Expanding the Power of the IT-ACTS Platform

At the heart of Powerhouse Therapeutics’ innovation is our Immune Triad Therapy with Armed CAR T-cell Supercharger (IT-ACTS), a proprietary cell-based platform that functions as a “living drug.” Acting like a miniature factory within the body, IT-ACTS continuously produces therapeutic agents and delivers them with pinpoint accuracy to diseased tissues. While initially focused on cancer—including some of the most treatment-resistant solid tumors—this platform is being developed for a wide range of indications, enabling the targeted elimination of pathogenic cells in various diseases and disorders. In addition to its immediate impact, IT-ACTS is engineered to sustain a durable, long-term immune response, offering benefits that extend far beyond the first course of treatment.

A hallmark of IT-ACTS is its adaptability and scalability. Because it can be loaded with diverse immune modulators, signaling molecules, and disease-associated antigens, IT-ACTS can be easily customized for different clinical needs and disease states. By delivering therapeutic agents directly where they are needed, it spares healthy tissues and enhances overall safety. Whether addressing cancer, tackling difficult chronic infections, or treating other pathologies, IT-ACTS can be tailored to deliver optimal outcomes in a broad spectrum of clinical scenarios.

Autologous and Allogeneic Versatility

An additional advantage of the IT-ACTS platform is its ability to be deployed in both autologous and allogeneic settings. For patients who need a highly personalized approach, autologous therapies leverage their own cells, reducing the risk of immune rejection. Meanwhile, allogeneic “off-the-shelf” products can be rapidly manufactured and broadly distributed, making them more accessible and potentially more cost-effective. This dual-pronged capability ensures IT-ACTS can meet diverse clinical and operational needs, driving faster innovation and broader patient impact.

A Commitment to Safety Without Compromise

Built with patient safety as a guiding principle, IT-ACTS minimizes off-target effects, leading to little to no side effects. Its self-contained, living-drug design allows for potent, localized treatment while avoiding many toxicities commonly associated with traditional systemic therapies. Patients can receive treatment with greater ease and confidence, knowing that IT-ACTS is designed to maximize efficacy while preserving quality of life.

Broad Clinical Potential Across Indications

The versatility of IT-ACTS makes it suitable for an array of diseases, from solid tumors such as liver, colorectal, pancreatic, and ovarian cancers to other hard-to-treat conditions such as fibrosis. Its robust safety profile is particularly advantageous for patients who cannot tolerate existing treatments due to severe side effects. By incorporating specific immune modulators and targeted payloads, IT-ACTS overcomes key resistance mechanisms across varied disease settings, boosting effectiveness without compromising safety.

Moreover, IT-ACTS seamlessly integrates with combination therapies. Whether paired with checkpoint inhibitors, cancer vaccines, senolytics, cytokine therapies, or other immunomodulatory treatments, IT-ACTS amplifies therapeutic responses and fills gaps in existing therapies. Critically, these combination regimens maintain a low side-effect profile, allowing patients to benefit from a comprehensive, multi-pronged approach without added safety concerns. This synergy heralds a new frontier in treatment, offering transformative hope for patients, clinicians, and the broader medical community.